## (19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 16 December 2004 (16.12.2004)

**PCT** 

# (10) International Publication Number WO 2004/108095 A1

 $(51) \ \ International \ Patent \ Classification ^7:$ 

A61K 6/06

(21) International Application Number:

PCT/NL2004/000396

(22) International Filing Date: 3 June 2004 (03.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

03076770.1 5 June 2003 (05.06.2003) EP 60/475,903 5 June 2003 (05.06.2003) US

- (71) Applicant (for all designated States except US): STICHT-ING GLASS FOR HEALTH [NL/NL]; J. Van Maerlantlaan 9, NL-2343 JX Oegstgeest (NL).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): VAN DEN BOSCH, Willem [NL/NL]; J. Van Maerlantlaan 9, NL-2343 JX Oegstgeest (NL). VAN DUINEN, Raimond, Nicolaas, Bruno [NL/NL]; A. Kropholterstraat 17, NL-2552 XV Den Haag (NL).
- (74) Agents: VAN WESTENBRUGGE, Andries et al.; Nederlandsch Octrooibureau, Scheveningseweg 82, P.O. Box 29720, NL-2502 LS The Hague (NL).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SELF HARDENING GLASS CARBOMER COMPOSITION

(57) Abstract: The present invention relates to a self hardening glass carbomer composition obtainable by treating a fluorosilicate glass powder with: (a) a poly(dialkylsiloxane) having terminal hydroxyl groups, wherein the alkyl groups contain 1 to 4 carbon atoms, (b) an aqueous acid solution, and (c) separating the treated fluorosilicate glass powder from the aqueous acid solution. The glass carbomer compositions according to the invention have for example good toughness and strength and excellent fluoride release, In addition, the glass carbomer compositions according to the invention do not show shrinkage or expansion, an essential property for providing fillings for cavities having high strength and long durability. Moreover, the glass carbomer composition according to the present invention has a lower sensitivity towards abrasion and wear, a greater stiffness, a smoother surface, a better colourfastness, a better adherence to e.g. bone tissue and a lower water sensitivity.



1

# SELF HARDENING GLASS CARBOMER COMPOSITION

### FIELD OF THE INVENTION

The present invention relates to a glass carbomer cement having improved properties, a method for preparing said glass carbomer cement and the use of said glass carbomer cement in clinical and dental applications including high stress applications, e.g. tooth restoration, dentine replacement, crown core build-ups, i.e. as bone and dental cement, and industrial applications.

10

15

20

25

30

5

#### BACKGROUND OF THE INVENTION

Glass ionomer cements are known in the art and are used for already a considerable period of time in clinical and dental applications, e.g. as a permanent filling material. For example, US 4.376.835 that is incorporated by reference herein discloses a calcium aluminium fluorosilicate glass powder having a average particle size of at least 0.5 µm, a depleted calcium level at the surface of the powder particles relative to the calcium level present in the core region of the powder particles, a ratio of the Si/Ca atomic ratio at the surface of the powder particles and the Si/Ca atomic ratio in the core region of the powder particles of at least 2.0, wherein the calcium content increases asymptotically from the surface to the core region. The calcium aluminium fluorosilicate glass powder according to US 4.376.835 has a reduced water sensitivity during and after the setting reaction and is used in a self-hardening glass ionomer cement comprising an aqueous mixture of said calcium aluminium fluorosilicate glass powder, a polycarboxylic acid and a chelating agent, wherein the polycarboxylic acid catalyses the setting or hardening reaction of the calcium aluminium fluorosilicate glass powder and the chelating agent accelerates and improve the setting or hardening reaction.

US 5.063.257, incorporated by reference herein, addresses for example the disadvantages of some glass ionomer cements known in the art. One of the most important disadvantages of these materials is that the setting or hardening reaction is difficult to control thereby leading to cements that are embrittled at the surface and therefore have a reduced strength. US 5.063.257 provides a solution for this problem by

2

employing a glass ionomer cement composition comprising a fluorosilicate glass powder, a polymer of an  $\alpha,\beta$ -unsaturated carboxylic acid, e.g. poly(acrylic acid), a polymerisable organic compound having unsaturated carbon-carbon bonds, a polymerisation catalyst, water, a surface active agent and a reducing agent. The setting or hardening of this composition occurs by the usual neutralisation reactions of the fluorosilicate glass powder as well as polymerisation reactions of the unsaturated groups present in the polymer of an  $\alpha,\beta$ -unsaturated carboxylic acid and the polymerisable organic compound thereby giving a glass ionomer cement that is far less sensitive to water at the initial stage of setting or hardening. According to Examples 6 and 8 and 14-16, the fluorosilicate glass powder is pre-treated with an ethylenically unsaturated alkoxysilane, e.g. vinyltris( $\beta$ -methoxyethoxy)silane.

5

10

15

20

25

30

US 5.453.456, US 5.552.485 and US 5.670.258, all incorporated by reference, disclose fluorosilicate glass powders that are treated with an aqueous silanol treating solution and optionally an additional organic compound. These treated fluorosilicate glass powders can form cements having an improved strength. The aqueous silanol treating solutions are prepared *in situ*, preferably by hydrolysis of acidic ethylenically unsaturated alkoxysilanes, i.e. alkoxy silanes having preferably one or more hydrolysable alkoxy groups, one or more ethylenically unsaturated groups and one or more carboxylic groups.

Commercially available products are for example KetacMolar® from 3M ESPE and Fuji IX® from GC Corp.

However, the glass ionomer cements known from the prior art still suffer from several disadvantages. For example, the strength, stiffness and hardness of the glass ionomer cements according to the prior art is often insufficient. The surface of the known cements – when hardened - are also not very smooth with the result that, when e.g. employed as dental filing material, they are difficult to polish. Another disadvantage of the known glass ionomer cements is that the hardened cement has a rather high solubility which causes wear of the dental filling. The hardened cements also show a rather poor adherence to bone tissue. Consequently, there is still a need for improved glass ionomer cements that do suffer from these disadvantages.

In conclusion, the glass ionomer compositions according to the prior art are in particular inferior with respect to sensitivity towards abrasion and aesthetic properties. Moreover, they often show insufficient strength.

3

It is therefore an object of the invention to provide a glass ionomer composition (in the description reference is in general made to glass carbomer composition but both terms may be used interchangeably) that — when hardened - has improved properties with respect to the glass ionomers known in the art.

5

10

15

20

25

30

# SUMMARY OF THE INVENTION

All the methods known from the prior art that provide improved glass ionomers compositions are laborious and complicated. The present invention provides a solution for this technical problem without deteriorating effects. The glass carbomer composition according to the invention is manufactured from commonly available materials and it shows — either in the unhardened state or the hardened state - even a better performance when compared to the glass ionomer compositions known from the prior art. The glass carbomer compositions according to the invention have for example good toughness and strength and excellent fluoride release. In addition, the glass carbomer compositions according to the invention do not show shrinkage or expansion, an essential property for providing fillings for cavities having high strength and long durability.

In addition, the glass carbomer composition according to the present invention has - when hardened - in particular a higher hardness, a lower sensitivity towards abrasion and wear, a greater stiffness, a lower solubility, a smoother surface, a better colourfastness, a better adherence to e.g. bone tissue and a lower water sensitivity. Another advantage of the glass carbomer composition according to the invention is that when hardened it can be polished much easier in comparison with the known glass ionomer compositions. Further advantages of the glass carbomer composition according to the present invention is that the unhardened glass carbomer composition shows a better fluidity so that cavities are much easier to fill, a better processability and a shorter hardening time. The glass carbomer composition according to the present is also much easier to use as sealing material. All these advantages are apparent from preliminary clinical trials.

The present invention therefore relates to a self hardening glass carbomer composition obtainable by treating a fluorosilicate glass powder with:

4

- (a) a poly(dialkylsiloxane) having terminal hydroxyl groups, wherein the alkyl groups contain 1 to 4 carbon atoms,
  - (b) an aqueous acid solution,

5

10

15

20

25

30

(c) separating the treated fluorosilicate glass powder from the aqueous acid solution.

#### DETAILED DESCRIPTION OF THE INVENTION

The fluorosilicate glass powder particles employed in this invention are generally depleted of calcium at their surface such that the quotient of the atomic ratio Si/Ca at the surface of the powder particles and the atomic ratio Si/Ca in the core region is at least 2.0, preferably at least 3.0, and most preferably at least 4.0. The calcium content of the powder particles of the invention increases asymptotically from the surface to the core region.

The depth of the depletion zone depends on the conditions given in each individual case. However, the depletion zone preferably extends at least to a depth of about 10 nm, more preferably to at least about 20 nm, and most preferably to at least about 100 nm. These ranges are particularly suited for use of the fluorosilicate glass powders in dentistry. For other purposes, e.g., for use in bone cements, the depletion zone may also be deeper and may be 200 to 300 nm, for example.

As is known in the art, the fluorosilicate glass powders are produced by surface treatment of glass powders having a composition corresponding to the core region of the powders. Upon surface treatment the number of silicon atoms per unit volume remains substantially constant. The actual change in the absolute number of atoms per unit volume of other types of atoms is therefore obtained by forming the quotient of the relative atom proportion with the percentage silicon proportion. The quotient of the atomic ratio Si/Ca at the surface and the atomic ratio Si/Ca in the core region therefore constitutes a useful value to characterise the fluorosilicate glass powders.

The surface measurement to determine Ca depletion of the glass powders of the invention is suitably carried out by photo electron spectroscopy for chemical analysis (ESCA). This method has been described by R. S. Swingle II and W. M. Riggs in Critical Reviews in Analytical Chemistry, Vol. 5, Issue 3, pages 267 to 321, 1975 and by K. Levsen in "Chemie in unserer Zeit", Vol. 40, pages 48 to 53, 1976. The

5

10

15

20

25

30

5

measuring data underlying the description presented above are outlines in US 4.376.835.

The fluorosilicate glass powders have an average particle size (weight average) of at least 0.5 μm, preferably at least 1.0 μm, and most preferably at least 3.0 μm. For dental purposes the average particle size (weight average) is 1.0 to 20.0 μm, preferably 3.0 to 15.0 μm, most preferably 3.0 to 10.0 μm. The particles have a maximum particle size of 150 μm, preferably 100 μm, especially 60 μm. For use as dental bonding cement the maximum particle size is 25 μm, preferably 20 μm. In order to achieve good mechanical properties a not excessively narrow particle size distribution is favourable, as usual, which is achieved, for example, by conventional grinding and classifying of the coarse.

The fluorosilicate glass powders are prepared from glass powders having the average composition of the core region of the powders of the invention. To this end the glass powders described, for example, in DE A 2.061.513 and in Table I are suitable. The glass powders employed as starting materials are obtained as usual by fusing the starting components together at temperatures above 950°C., quenching, and grinding. The starting components may be, for example, the compounds stated in DE A 2.061.513 in suitable quantitative ranges.

The thus obtained powders are then subjected to a surface treatment. The powders of the invention are obtainable, for example, by removal of Ca by suitable chemical agents.

For example, the starting glass powders are treated on the surface with acid, preferably at room temperature. To this end substances containing acidic groups are employed, preferably substances forming soluble calcium salts. Sparing water-solubility of the respective calcium salts may be compensated to a certain degree by a large amount of liquid per unit of powder. The reaction period varies between a few minutes and several days, depending on the strength and concentration of the acid employed.

Thus, for instance, for the preparation of the powders hydrochloric, sulfuric, nitric, acetic, propionic and perchloric acid may be used.

The acids are employed at a concentration of 0.01 to 10% by weight, preferably from 0.05 to 3% by weight.

6

After the respective reaction period the powders are separated from the solution and thoroughly washed to leave substantially no soluble calcium salts on the surface of the powder particles. Finally the powder is dried, preferably above 70°C, and screened to the desired particle size ranges.

The stronger the acid employed and the longer a given acid acts on the powder the longer will be the processing period after mixing with the mixing fluid.

5

10

15

20

25

30

The favourable surface character of the powders permits the use of an especially high powder/fluid ratio in the cement mix resulting in high strength values of the hardened material. The possibility of using a particularly reactive mixing fluid has the same effect. Furthermore, the processing period of a cement of the invention may be tailored to meet the user's requirements. The length of the processing period hardly influences the subsequent hardening period, so that also upon long processing periods rapid setting and early water insensitivity occurs.

The glass powders may be mixed, to form dental cements or bone cements, with the conventional aqueous polycarboxylic acid solutions as described, for example, in DE A 2.061.513, DE A 2.439.882 and DE A 2.101.889. Suitable polycarboxylic acids are polymaleic acid, polyacrylic acid and mixtures thereof, or copolymers, especially maleic acid/acrylic acid copolymers and/or acrylic acid/itaconic acid copolymers. It is self-evident that with the use of an extremely reactive glass powder a less reactive polycarboxylic acid will be employed in order to obtain a satisfactory hardening characteristic.

In order to accelerate and improve hardening of said glass ionomer cements chelating agents may be added during mixing, in a manner known from DE A 2.319.715. Instead of the customary use of the aqueous polycarboxylic acid solution as mixing fluid, the glass powder may also be pre-mixed in the corresponding ratio with the dry powdered polycarboxylic acid, as the solid substances do not undergo reaction with each other. In that case water is used as mixing fluid, preferably an aqueous solution of a chelating agent together with conventional additives such as bacteriostatic agents, if appropriate.

In order to avoid metering errors and to attain optimum mechanical properties, the powders may be used in pre-dosaged form. For example, the glass powder is metered out in plastic containers. Then the cement can either be mixed mechanically within said plastic capsules, or the container may be emptied and the mix prepared by

7

hand. The aqueous polycarboxylic acid solution in such a case is metered, for example, with a dripping bottle or with a syringe. The use of the powder of the invention in so-called shaker capsules, e.g., corresponding to DE A 2.324.296, is suitable. A predetermined quantity of powder is held in readiness in a so-called main compartment, while the fluid is contained in a separate cushion beneath a lateral clip. By exerting pressure on said clip the fluid is sprayed through a bore into the main compartment and is then available for mechanical mixing. In both types of capsules the pure glass powder may be replaced by a mixture of glass powder and dry polycarboxylic acid in predetermined quantities. The fluid component is then water or an aqueous solution of a chelating agent.

5

10

15

20

25

30

The use of the mixture of glass powder and dry polycarboxylic acid is especially advantageous if said mixture is pelletised. To this end, the dry polycarboxylic acid is used in finely divided form after removal of coarse portions. After thorough blending of said polycarboxylic acid powder with the glass powder pellets may be made in a conventional pelletising machine. The compacting pressure must be selected such that after the addition of the mixing fluid (water or aqueous tartaric acid solution, for example), the pellets can still be readily worked into a cement while, on the other hand, they possess sufficient mechanical stability for transportation. Pellets made in this way permit especially simple mixing into a cement paste after brief dissolution, e.g., in the corresponding amount of tartaric acid solution. The mixing fluid may be added, for example, from a drip bottle or from a syringe.

According to the invention, the poly(dialkylsiloxane) may be linear or cyclic. It may further be a blend of different poly(dialkylsiloxane)s, e.g. a blend of a poly(dimethylsioxane) of high kinematic viscosity and a poly(dimethylsiloxane) of low kinematic viscosity. It is further preferred that the alkyl groups of the poly(dialkylsiloxane) are methyl groups. The kinematic viscosity is preferably in the range of about 1 cSt to about 100.000 cSt at 25°C [about 1 to about 100.000 mm²/s], preferably about 100 cSt to about 10.000 cSt at 25°C [about 100 to about 10.000 mm²/s], even more preferably about 500 cSt to about 5000 cSt at 25°C [about 100 to about 10.000 mm²/s]. The best results are obtained with a viscosity of about 1000 cSt at 25°C [about 1000 mm²/s].

According to the invention, the particles of the fluorosilicate glass powder have preferably an average size of about 0.5 µm to about 200 µm, more preferably about 3

 $\mu m$  to about 150  $\mu m$ , even more preferably about 3  $\mu m$  to about 100  $\mu m$  and in particular about 20  $\mu m$  to about 80  $\mu m$ .

It is preferred that the aqueous acid solution comprises an inorganic acid or an organic acid. It is even more preferred that the aqueous acid solution comprises an organic acid, wherein the organic acid is preferably a polymer, e.g. a polyacrylic acid. According to the invention, the aqueous acid solution has a pH in the range of 2 to 7.

The present invention also relates to a process for the preparation of a self hardening glass carbomer composition. According to the process according to the invention, a fluorosilicate glass powder is treated with in subsequent order:

- (a) a poly(dialkylsiloxane) having terminal hydroxyl groups, wherein the alkyl groups contain 1 to 4 carbon atoms,
  - (b) an aqueous acid solution,
- (c) separating the treated fluorosilicate glass powder from the aqueous acid solution.

The present invention also relates to the use of the self hardening glass carbomer composition according to the invention as a (temporarily) dental filling material, a denting bonding cement and a bone cement. The self hardening glass carbomer composition according to the invention can also be used as bone replacing material in orthopaedic surgery, e.g. as implants or coating materials for joint cavities.

20

5

10

15

# **EXAMPLES**

# Example 1

- 25 The following compositions were prepared from the following ingredients:
  - (a) a polydimethylsiloxane having a kinematic vicsosity of 1000 cSt indicated by S20:
  - (b) a conventional fluorosilicate glass powder; and
  - (c) a conventional aqueous polyacrylate solution.
- The fluorosilicate glass powder and aqueous polyacrylate solution used to prepare the compositions were taken from A3 APLICAP capsules from 3M ESPE.
  - The amounts of the ingredients are listed in Table 1, wherein 5 wt.% additional fluorosilicate glass powder equals about 0.015 g fluorosilicate glass powder and

9

wherein 0.0015 g S20 equals about 1.6% additional liquid added to the normal quantity of aqueous polyacrylate solution (about 0.0920 g).

Table 1

5

Product	Composition	on relative to contents of
	commercial	ly available A3 APLICAP
		capsule
	S20 (g)	Additional fluorosilicate
		glass powder (wt.%)
4P	0.0015	5.00
5P	0.0015	6.25
6P	0.0015	7.50
8P	0.0015	10.00
12P	0.0045	15.00

### Example 2

10

15

20

The compositions according to Example 1 were evaluated in an in-vitro wear test in the ACTA-wear machine which is a three body wear system designed to simulate the wear that occurs in the oral cavity (cf. de Gee et al., 1994, 1996). Two reference materials (IFMC and KPFA; KPFA is KetacMolar® from 3M ESPE) were tested for comparison. In this test, two wheels (a first wheel containing the sample to be tested and a second wheel being an antagonist) rotate in different directions but with 15% difference in circumferential speed (called slip) while having near contact on the circumference. Test samples are situated on the circumference of the first wheel. The force with which the two wheels work against each other is adjusted 1t about 15 N. Both wheels are situated in slurry of rice flour and husks of while millet spray in a buffer solution. During the wear test, the food is pressed between the wheels creating a wear track into the test samples, leaving an untouched area at both sides of the reference for the determination of the wear. The material lost by wear was determined b evaluating 10 samples with a profilometer.

10

The samples were prepared in the first wheel (size approximately 10 x 15 x 3 mm). During setting, the compositions according to Example 1 were stored in a 100% relative humidity oven at 37°C. After being set, the samples were glued on the first wheel by using a cyanoacrylate glue. Thereafter, the sample wheel was wet ground until a uniform cylindrical outer surface was obtained. The wear grinding was performed in the wear testing machine with carburondrum and diamond wheels up to a grit of 1000. During this procedure, a layer of 100 µm was removed from the outer surface. Subsequently, the wear test was started which was conducted at 37°C and pH 7.0. Wear data were obtained after 1 day, 4 days and 8 days. The data obtained are shown in Table 2, wherein a rating of below 60 is acceptable wherein lower data equals a higher hardness.

Table 2

Time	IFMC	KPFA	5P	6P	8P	12P
(days)						
1	135.7	49.5	57.8	54.1	53.9	71.5
4	68.2	43.1	47.7	42.8	45.2	57.4
8	62.7	41.5	43.8	42.7	40.0	57.4

15

20

25

5

10

The data of Table 2 show that the hardness of the samples increase with time. From the data of Table 2, it is concluded that IFMC is inferior to all tested samples prepared from compositions according to the present invention. In addition, KPFA shows an infererior performance when compared with sample 8P according to the present invention.

## Example 3

In this example solubility tests were performed. The test was performed as follows. The weight of hardened samples having a diameter of about 0.4 to about 0.6 cm and having a thickness of about 1 to about 1.5 mm were was determined as reference. In the test, these samples were immersed in water at various pH values wherein the pH was adjusted with citric acid. A pH value of 2.5 was tested since it

11

simulates the pH that can occur in between molars. The test was performed over a period of about 15 days. At several time intervals the weight of the test samples was determined wherein a greater weight loss indicated a higher solubility of the material. The data are expressed as % solubility (calculated on the original weight and the weight loss at the indicated periods) and are shown in Table 3.

Table 3

Time (h)	pH 2.5		pH 3.2		pH 7.0	
	KPFA		KPFA	5P	KPFA	5P
0.0	0.0	0.0	0.0	0.0	0.0	0.0
1.5	12.1	11.7	7.1	5.0	_	-
72.0	20.2	16.9	10.9	8.0	2.6	1.1
144.0	25.2	19.2	19.9	14.2	-	-
360.0	27.4	21.6	19.9	16.3	5.5	1.8

10

5

From the data in Table 3 it appears that the sample prepared from the composition according to the invention showed an improved solubility performance than the commercially available material KPFA.

WO 2004/108095

5

25

PCT/NL2004/000396

12

### Claims

- 1. A self hardening glass carbomer composition obtainable by treating a fluorosilicate glass powder with:
- (a) a poly(dialkylsiloxane) having terminal hydroxyl groups, wherein the alkyl groups contain 1 to 4 carbon atoms,
  - (b) an aqueous acid solution,
  - (c) separating the treated fluorosilicate glass powder from the aqueous acid solution.
- 2. Self hardening glass carbomer composition according to claim 1, wherein the poly(dialkylsiloxane) is linear or cyclic.
  - 3. Self hardening glass carbomer composition according to claim 1 or claim 2, wherein the alkyl groups of the poly(dialkylsiloxane) are methyl groups.
- 4. Self hardening glass carbomer composition according to any one of claims 1 3,
  15 wherein the poly(dialkylsiloxane) has a kinematic viscosity in the range of about
  1 to about 100.000 cSt at 25°C.
  - 5. Self hardening glass carbomer composition according to any one of claims 1-4, wherein the particles of the fluorosilicate glass powder have an average size of about 0.5 to about 200  $\mu$ m.
- 20 6. Self hardening glass carbomer composition according to any one of claims 1-5, wherein the aqueous acid solution comprises an inorganic acid or an organic acid.
  - 7. Self hardening glass carbomer composition according to claim 6, wherein the organic acid is a polymer.
  - 8. Self hardening glass carbomer composition according to any one of claims 1-7, wherein the aqueous acid solution has a pH in the range of 2 to 7.
    - 9. Process for the preparation of a self hardening glass carbomer composition, wherein a fluorosilicate glass powder is treated with:
    - (a) a poly(dialkylsiloxane) having terminal hydroxyl groups, wherein the alkyl groups contain 1 to 4 carbon atoms,
- 30 (b) an aqueous acid solution,
  - (c) separating the treated fluorosilicate glass powder from the aqueous acid solution.

13

10. Use of the self hardening glass carbomer composition according to any one of claims 1-8 as a dental filling material, a denting bonding cement, a bone cement or a bone replacing material

In tional Application No Pt I/NL2004/000396

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K6/06

According to International Patent Classification (IPC) or to both national classification and IPC

#### **B. FIELDS SEARCHED**

 $\label{eq:minimum} \begin{array}{ll} \text{Minimum documentation searched (classification system followed by classification symbols)} \\ IPC 7 & A61K \end{array}$ 

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 376 835 A (GASSER OSWALD ET AL) 15 March 1983 (1983-03-15) cited in the application column 1, lines 17-30 column 2 - column 3	1-10
A	US 5 453 456 A (MITRA SUMITA B ET AL) 26 September 1995 (1995-09-26) cited in the application column 2, lines 2-8,18-34 column 3, lines 24,25	1-10
A	DE 32 48 357 A (ESPE PHARM PRAEP) 5 July 1984 (1984-07-05) page 8, lines 15-32 page 9, line 24 - page 10, line 3	1-10

	<u></u>
<ul> <li>Special categories of cited documents:</li> <li>"A" document defining the general state of the art which is not considered to be of particular relevance</li> <li>"E" earlier document but published on or after the international filing date</li> <li>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</li> <li>"O" document referring to an oral disclosure, use, exhibition or other means</li> <li>"P" document published prior to the international filing date but later than the priority date claimed</li> </ul>	<ul> <li>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</li> <li>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</li> <li>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</li> <li>*&amp;* document member of the same patent family</li> </ul>
Date of the actual completion of the international search	Date of mailing of the international search report
24 September 2004	11/10/2004
Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Böhm, I

Y Patent family members are listed in annex.

Y Further documents are listed in the continuation of box C.

In tional Application No
PCT/NL2004/000396

	tion) DOCUMENTS CONSIDERED TO BE RELEVANT	In the second second
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 063 001 A (ZLOCHOWER ISAAC A) 13 December 1977 (1977-12-13) column 1, lines 11,12 column 2, lines 28-42 column 3, lines 8-36 column 4, lines 63-67	1-10

national application No. PCT/NL2004/000396

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 10 is directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

Int ional Application No PCT/NL2004/000396

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 4376835	A	15-03-1983	DE	2929121 A1	12-02-1981
	, ,		AT	1336 T	15-07-1982
			ΑÜ	534012 B2	22-12-1983
			AU	6061180 A	22-01-1981
			CA	1156679 A1	08-11-1983
			DE		02-09-1982
			EP	3060667 D1	
				0023013 A2	28-01-1981
			JP	1229597 C	19-09-1984
			JP	56017943 A	20-02-1981
			JP	59005536 B	06-02-1984
			JP	1622085 C	09-10-1991
			JP	2039465 B	05-09-1990
			JP	59010872 A	20-01-1984
US 5453456	Α	26-09-1995	US	5332429 A	26-07-1994
			US	5552485 A	03-09-1996
			US	5670258 A	23-09-1997
			ĂÜ	670913 B2	08-08-1996
			AU	2160892 A	08-01-1993
			AU	683600 B2	13-11-1997
			ΑÜ	5464696 A	01-08-1996
			BR	9206070 A	15-11-1994
			CA	2110265 A1	10-12-1992
			DE	69218202 D1	17-04-1997
			DE	69218202 T2	16-10-1997
			EP	0588950 A1	
			HK		30-03-1994
				1007732 A1	23-04-1999
			JP	3492682 B2	03-02-2004
			JP	6508337 T	22-09-1994
			JP	2001072688 A	21-03-2001
			MX	9202564 A1	01-05-1993
			NO	934304 A	31-01-1994
			MO	9221632 A2	10-12-1992
			ZA	9203911 A	24-02-1993
DE 3248357	Α	05-07-1984	DE	3248357 A1	05-07-1984
			ΑT	32182 T	15-02-1988
			DE	3375457 D1	03-03-1988
			EP	0115058 A2	08-08-1984
			JP	1622100 C	09-10-1991
			JP	2044443 B	04-10-1990
			JΡ	59130805 A	27-07-1984
			ÜS	4527979 A	09-07-1985
			-	"IULIJIJ R	05 07 1905
US 4063001	Α	13-12-1977	US	4046948 A	06-09-1977